obexelimab

Zenas adds $200M series C to reach a bucket of key readouts for its lead monoclonal antibody
Fierce Biotech
Tue, 05/7/24 - 10:58 am
Zenas BioPharma
funding
monoclonal antibodies
obexelimab
autoimmune disease
Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal
Fierce Biotech
Mon, 11/22/21 - 10:37 am
Xencor
obexelimab
Zenas BioPharma
autoimmune disease